Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 in dedifferentiated liposarcoma
NCT05496569Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of culmerciclib in dedifferentiated liposarcoma (DDL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2022; status: terminated.
02
Drugs
culmerciclib
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT05496569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496569.